ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01093521
Recruitment Status : Active, not recruiting
First Posted : March 26, 2010
Results First Posted : January 12, 2016
Last Update Posted : May 15, 2017
Sponsor:
Collaborator:
Cystic Fibrosis Foundation Therapeutics
Information provided by (Responsible Party):
Chris Goss, University of Washington

March 24, 2010
March 26, 2010
September 15, 2014
January 12, 2016
May 15, 2017
April 2010
April 2012   (Final data collection date for primary outcome measure)
  • Pharmacokinetic Assessment of a 5 Day Infusion of Gallium Nitrate (IV Ganite®) [ Time Frame: Day 1 at t=1, 2 and 6 hours, Day 3, Day 6 at t= 1, 2, 8, and 12, Day 14 and Day 28 ]

    To assess the summed area under the curves of a 5 day infusion of IV Ga from day 1 to day 28 at two doses: 100 mg/m2/day in adult subjects with CF; 200 mg/m2/day in adult subjects with CF.

    To assess the safety of a 5 day infusion of IV Ga at two doses: 100 mg/m2/day in adult subjects with CF; 200 mg/m2/day in adult subjects with CF.

    Safety and tolerability of 5 days of treatment with IV administered gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day.

  • Number of Serious Adverse Events [ Time Frame: 56 days from starting dose ]
    Safety as measured by serous adverse events
  • Number of Events When Study Drug Infusion Was Stopped Early [ Time Frame: 6 days from starting dose ]
    Tolerability as measured by adverse events of a 5 day continuous infusion of IV Gallium as assessed by stopping study drug infusion
Pharmacokinetic, safety, and tolerability assessment of a 5 day infusion of gallium nitrate (IV Ganite®) [ Time Frame: 28 days ]

To assess the pharmacokinetics of a 5 day infusion of IV Ga at two doses: 100 mg/m2/day in adult subjects with CF; 200 mg/m2/day in adult subjects with CF.

To assess the safety of a 5 day infusion of IV Ga at two doses: 100 mg/m2/day in adult subjects with CF; 200 mg/m2/day in adult subjects with CF.

Safety and tolerability of 5 days of treatment with IV administered gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day.

Complete list of historical versions of study NCT01093521 on ClinicalTrials.gov Archive Site
  • Change in Spirometry From Baseline to Day 8 [ Time Frame: 8 days ]
    Change in spirometry as measured by FEV1 in liters from baseline to day 8
  • Change in Lung Function From Baseline to Day 15 [ Time Frame: 15 days from starting dose ]
    Change in FEV1 in liters from baseline to day 15
  • Change in Spirometry From Baseline to Day 28 [ Time Frame: 28 days from starting dose ]
    Change in lung function as measured by FEV1 in liters from baseline to day 28
  • Change in Spirometry From Baseline to Day 56 [ Time Frame: 56 days from starting dose ]
    Change in lung function as measured by FEV1 in liters from baseline to day 56
  • Change in Spirometry as Measured by FVC From Baseline to Day 8 [ Time Frame: 8 days from starting dose ]
    Change from baseline in lung function assessed by FVC in liters after treatment with IV Ga at day 8
  • Change in P. Aeruginosa Density From Baseline to Day 8 [ Time Frame: 8 days from starting dose ]
    Change in sputum microbiology (specifically P. aeruginosa density based on quantitative cultures) from baseline to day 8
  • Change in Sputum P. Aeruginosa Density From Baseline to Day 15 [ Time Frame: 15 days from starting dose ]
    Change in sputum microbiology (specifically P. aeruginosa density based on quantitative cultures) from baseline to day 15
  • Change in P. Aeruginosa Density From Baseline to Day 56 [ Time Frame: 56 days from starting dose ]
    Change in sputum microbiology (specifically P. aeruginosa density based on quantitative cultures) from baseline to day 56
Change in spirometry, change in sputum microbiology [ Time Frame: 28 days ]

Change in spirometry from baseline to day 8, from baseline to day 15 and from baseline to day 28.

Change from baseline in FEV1 after treatment with IV Ga. Change from baseline in FVC after treatment with IV Ga.

Change in sputum microbiology (specifically P. aeruginosa density based on quantitative cultures) from baseline to day 8, from baseline to day 15, and from baseline to day 28

Not Provided
Not Provided
 
A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients
A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients

The purpose of this research study is to test the pharmacokinetics, safety, and tolerability of an intravenous infusion of a drug called Ganite (gallium nitrate) in patients with cystic fibrosis. We want to see this drug is safe and tolerable and to see if high levels of the drug are found in the sputum.

Funding Source - Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD)

This is a two center pharmacokinetic and safety dosing study of IV gallium nitrate (Ganite®) in cystic fibrosis (CF) patients. Eighteen subjects are planned. Each subject will be administered a single 5-day infusion of study medication (one of 2 doses). No placebo is used. Each subject will receive 5 days of continuous infusion of the experimental treatment. There will be two dosing cohorts (cohort 1: 100 mg/m2/day and cohort 2: 200 mg/m2/day). Cohort 2 will begin enrollment only after Data Safety Monitoring Committee (DSMC) safety review and approval of cohort 1 data. Study visits occur at baseline (day 1), day 3 (visit 2), day 6 (visit 3), day 8 (visit 4), day 14 (visit 5), day 28 (visit 6), and day 56 (visit 7).

Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study.

The following treatment regimens will be used:

• Experimental treatment continuous infusion of gallium nitrate at the following doses cohort 1: 100 mg/m2/day and cohort 2: 200 mg/m2/day All subjects who receive at least one dose of study medication will be considered evaluable for safety and efficacy analyses. Incidence of adverse events will be monitored during the trial.

Primary endpoints will be assessment of pharmacokinetic and safety/tolerability data.

Secondary efficacy assessments will be based on changes in lung function and sputum P. aeruginosa density in sputum.

Total duration of subject participation will be five weeks. Total duration of the study is expected to be 20 months.

Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Cystic Fibrosis
  • Drug: 100 mg/m2 dose
    5 day infusion of gallium nitrate (IV Ganite®) at a dose of 100 mg/m2/day
    Other Names:
    • Ganite®
    • gallium nitrate
  • Drug: 200 mg/m2 dose
    5 day infusion of gallium nitrate (IV Ganite®) at 200 mg/m2/day
    Other Names:
    • Ganite®
    • gallium nitrate
  • Experimental: 100 mg/m2 dose
    Five day continuous IV Gallium Nitrate (Ganite®) infusion at 100 mg/m2
    Intervention: Drug: 100 mg/m2 dose
  • Experimental: 200 mg/m2 dose
    Five day continuous IV Gallium Nitrate (Ganite®) infusion at 200 mg/m2
    Intervention: Drug: 200 mg/m2 dose
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
20
18
September 2018
April 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Adult male or female, between 18 and 55 years of age
  2. Documented chronic colonization with Pseudomonas Aeruginosa (Pa)
  3. Confirmed diagnosis of CF:

    1. Documented history of > 60 mmol/L chloride concentration in pilocarpine sweat chloride test And/Or
    2. Genotype with two identifiable mutations consistent with CF, accompanied by one or more phenotypic features consistent with diagnosis of CF
  4. Forced expiratory volume in the first second (FEV1) ≥ 30% of predicted value
  5. Able to expectorate sputum
  6. Serum liver function tests ≤ 2.5 x upper limit of normal
  7. Serum urea nitrogen (BUN) and creatinine ≤ 1.5 x upper limit of normal
  8. Serum creatinine ≤ 2.0 mg/dl
  9. Hemoglobin ≥ 9 g/dl, platelets ≥ 100,000/mm3, and white blood cells (WBC) ≥ 4,500/mm3 and ≤ 15,000/mm3
  10. Ionized calcium ≥ the lower limit of normal
  11. Able to understand and sign the informed consent document, communicate with the Investigator, and comply with the requirements of the protocol
  12. If female and of childbearing potential, must have a negative pregnancy test on Day 1 prior to receiving study drug
  13. If female and of childbearing potential, is willing to use adequate contraception, as determined by the investigator, for the duration of the study

Exclusion Criteria:

  1. Acute pulmonary exacerbation requiring antibiotic intervention within 2 weeks prior to screening
  2. Osteoporosis defined as the most recent dexa scan within the prior 5 years with a T-score ≤ -2.5
  3. Pregnant or lactating female
  4. Known sensitivity to gallium
  5. Use of biphosphonates
  6. Use of any investigational drug and/or participated in any clinical trial within 3 months prior to screening
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01093521
35876
US FDA 5R01FD003704 ( Other Grant/Funding Number: FDA )
Yes
Not Provided
Not Provided
Chris Goss, University of Washington
University of Washington
Cystic Fibrosis Foundation Therapeutics
Principal Investigator: Christopher H Goss, MD, MSc University of Washington
University of Washington
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP